Review: Cholinesterase inhibitors may be effective in Alzheimer disease

January 2006
ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p19
Academic Journal
The article presents a clinical study according to which cholinesterase inhibitors for patients with Alzheimer's disease (AD). Randomized controlled trials that compared cholinesterase inhibitors with placebo in patients with AD. Studies that did not examine clinical outcomes or focused on vascular dementia were excluded. Measures of clinical outcome included Alzheimer's Disease Assessment-Cognitive Subscale, Clinician's Interview Based Impression of Change scale plus caregiver input, Clinical Global Impression of Change, Progressive Deterioration Scale, etc. A limited and methodologically flawed evidence base suggests that treatment with cholinesterase inhibitors marginally improves clinical outcomes in Alzheimer disease.


Related Articles

  • Long-Term Cholinesterase Inhibitor Treatment of Alzheimer’s Disease. Johannsen, Peter // CNS Drugs;2004, Vol. 18 Issue 12, p757 

    The most prevalent cause of dementia – Alzheimer’s disease – is characterised by an early cholinergic deficit that is in part responsible for the cognitive deficits, especially memory and attention defects, seen with this condition. Three cholinesterase inhibitors (ChEIs),...

  • A Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Safety and Tolerability of Two Doses of Divalproex Sodium in Outpatients with Probable Alzheimer's Disease. Profenno, Louis A.; Jakimovich, Laura; Holt, Connie J.; Porsteinsson, Anton; Tariot, Pierre N. // Current Alzheimer Research;Dec2005, Vol. 2 Issue 5, p553 

    OBJECTIVE: The Alzheimer's Disease Cooperative Study (ADCS) is conducting a clinical trial to address whether chronic valproate treatment can delay emergence of behavioral symptoms in outpatients with AD. Since there were no data on the safety and tolerability of divalproex sodium in outpatients...

  • Medivation's Dimebon Meets Goal in Huntington's Study. Hollingsworth, Catherine // BioWorld Today;7/9/2008, Vol. 19 Issue 132, p1 

    The article details the results of the Phase II study of 90 Huntington's Disease (HD) patients who are Dimebon-treated. Dimebon is considered to be safe, well-tolerated and has notably enhanced the cognitive activities of the patients compared to placebo. According to chief executive officer...

  • Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder. Ribeiz, Salma R. I.; Bassitt, Débora P.; Arrais, Jony A.; Avila, Renata; Steffens, David C.; Bottino, Cássio M. C. // CNS Drugs;2010, Vol. 24 Issue 4, p303 

    Background: Cognitive deficits have been described in patients with schizophrenia from the first descriptions of dementia praecox to current concepts of cognitive dysmetria. Nevertheless, little is known about how to deal with them. In Alzheimer disease, cholinergic deficit is found and...

  • Fixing Alzheimer Disease Trials by Improving Process and Methods. Schneider, Lon S. // Current Alzheimer Research;Oct2010, Vol. 7 Issue 7, p564 

    No abstract available.

  • Donepezil: A Review of its Use in Alzheimer's Disease. Dooley, M.; Lamb, H.M. // Drugs & Aging;2000, Vol. 16 Issue 3, p199 

    Donepezil (E-2020) is a reversible, noncompetitive, piperidine-type cholinesterase inhibitor. It is selective for acetylcholinesterase rather than butyrylcholinesterase. Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed...

  • A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimer's Type. Schneider, Lon S.; DeKosky, Steven T.; Farlow, Martin R.; Tariot, Pierre N.; Hoerr, Robert; Kieser, Meinhard // Current Alzheimer Research;Dec2005, Vol. 2 Issue 5, p541 

    Context: Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results. Objective: To determine the clinical efficacy of GbE in mild to moderate dementia of the Alzheimer type. Design: Randomized,...

  • Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. Ravina, B.; Puff, M.; Siderowf, A.; Farrar, J. T.; Gillespie, M.; Crawley, A.; Fernandez, H. H.; Trieschmann, M. M.; Reichwein, S.; Simuni, T. // Journal of Neurology, Neurosurgery & Psychiatry;Jul2005, Vol. 76 Issue 7, p934 

    Objective: To study the safely and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD). Methods: This was a randomised double blind, placebo controlled, crossover study in 22 subjects with PD and dementia. Participants were...

  • Rofecoxib in Patients with Mild Cognitive Impairment: Further Analyses of Data from a Randomized, Double-Blind, Trial. Aisen, Paul S.; Thal, Leon J.; Ferris, Steven H.; Assaid, Christopher; Nessly, Michael L.; Giuliani, Michael J.; Lines, Christopher R.; Norman, Barbara A.; Potter, William Z. // Current Alzheimer Research;Jan2008, Vol. 5 Issue 1, p73 

    A recent clinical trial in patients with Mild Cognitive Impairment (MCI) found an increased rate of possible or probable Alzheimer's disease (AD) diagnoses in patients assigned to rofecoxib compared to placebo. This unexpected finding was difficult to interpret due to methodological issues and a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics